These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 19732942

  • 1. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Res; 2010 Feb; 125(2):e40-5. PubMed ID: 19732942
    [Abstract] [Full Text] [Related]

  • 2. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Haemost; 2009 Jul; 102(1):49-55. PubMed ID: 19572067
    [Abstract] [Full Text] [Related]

  • 3. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D.
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [Abstract] [Full Text] [Related]

  • 4. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2007 Jan; 120(6):871-6. PubMed ID: 17331567
    [Abstract] [Full Text] [Related]

  • 5. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2007 Jan; 119(4):475-80. PubMed ID: 16828495
    [Abstract] [Full Text] [Related]

  • 6. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
    Małyszko J, Łebkowska U, Małyszko JS, Myśliwiec M.
    Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
    [Abstract] [Full Text] [Related]

  • 7. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment.
    Pawlak K, Tankiewicz J, Mysliwiec M, Pawlak D.
    Blood Coagul Fibrinolysis; 2009 Oct; 20(7):590-4. PubMed ID: 19491664
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
    Pawlak K, Ulazka B, Mysliwiec M, Pawlak D.
    Transl Res; 2012 Nov; 160(5):346-54. PubMed ID: 22683425
    [Abstract] [Full Text] [Related]

  • 9. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2006 Nov; 117(5):517-22. PubMed ID: 15964061
    [Abstract] [Full Text] [Related]

  • 10. Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Res; 2012 Jun; 129(6):704-9. PubMed ID: 21906785
    [Abstract] [Full Text] [Related]

  • 11. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 12. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
    Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C.
    Thromb Haemost; 2001 Nov; 86(5):1197-203. PubMed ID: 11816707
    [Abstract] [Full Text] [Related]

  • 13. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2008 Nov; 121(6):787-91. PubMed ID: 17869326
    [Abstract] [Full Text] [Related]

  • 14. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease.
    Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D.
    Thromb Res; 2009 Sep; 124(4):452-7. PubMed ID: 19477487
    [Abstract] [Full Text] [Related]

  • 15. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
    Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C, Reinke P.
    Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
    [Abstract] [Full Text] [Related]

  • 16. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
    Pawlak K, Pawlak D, Myśliwiec M.
    Thromb Res; 2008 Jun; 121(4):543-8. PubMed ID: 17706748
    [Abstract] [Full Text] [Related]

  • 17. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
    Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M.
    Exp Clin Endocrinol Diabetes; 2000 Jun; 108(7):486-92. PubMed ID: 11083070
    [Abstract] [Full Text] [Related]

  • 18. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 19. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC, Yang SF, Lue KH, Hsieh YS, Hsiao TY, Lu KH.
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [Abstract] [Full Text] [Related]

  • 20. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
    Kamiński TW, Pawlak K, Karbowska M, Myśliwiec M, Pawlak D.
    BMC Nephrol; 2017 Jan 25; 18(1):35. PubMed ID: 28122514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.